提醒

EMS-CHEMIE HOLDING AG (EMSN.SW)

Swiss: EMSN.SW · 即時價格 · USD

770.00

-1.00 (-0.13%)

收盤價： Aug 26, 2026, 5:19 PM

股價、關鍵數字和最新消息，都在這一頁。

-0.13% (1D)

買價	n/a
市值	17.99B
營收 (ttm)	1.97B
淨利（ttm）	466.5M
	0.81
	19.97
	38.51
	33.79
P/B (ttm)	9.70
P/S (ttm)	9.13
財報日期	Feb 5, 2027

賣價	n/a
成交量	8,164
20 日平均成交量	18,193
開盤價	769.00
前收盤價	771.00
當日區間	761.00 - 771.50
52 週範圍	530.00 - 839.50
分析師	n/a
目標價	720 (-6.49%)
股利	$14.65 (1.9%)
除息日	2026年8月11日

關於 EMSN.SW

EMS-CHEMIE HOLDING AG engages in the polymers and specialty chemicals businesses in the Americas, Europe, Asia, and internationally. The company manufactures and sells polymers, such as polyamide granulates used in automotive and construction applications in the electro and electronics, optics, and other industrial sectors, as well as offers feasibility studies, design, prototypes, component testing, and mould optimization services. It also offer...

[閱讀更多]

產業 Specialty Chemicals

類股 Basic Materials

IPO 日期 Dec 1, 2003

員工 2,657

證券交易所 Swiss

股票代號 EMSN.SW

網站 https://www.ems-group.com

完整的公司簡介

財務表現

EMS-CHEMIE HOLDING 在 2025 年的營收為 1.95B，較前一年的 2.07B 減少 -5.85%。淨利為 466.5M，較前期增加 1.24%。

CHF 中的財務資料財務報表

分析師預測

根據 7 位分析師的評等，EMSN.SW 的平均評等為「null」。12 個月目標價為 720，較最新價格有 6.49% 的下跌空間。

股票預測

下次財報發布

EMS-CHEMIE HOLDING AG 的下次財報預計於 Feb 5, 2027, 盤中。
分析師預估營收 ... 升級

新聞動態

10 月前 · Simply Wall St.

EMS-CHEMIE HOLDING (SWX:EMSN): Examining Valuation After Recent Share Price Weakness

EMS-CHEMIE HOLDING (SWX:EMSN) stock has shown slight movement recently, with the share price closing at CHF 558. Over the past month, the stock is down about 7%, which reflects continued market volati...

11 月前 · Packaging Gateway

Heineken’s Strongbow adds NaviLens levels to packaging

The cider brand has added a high-contrast NaviLens QR code to its cans.

11 月前 · The Bergen Record

3 firms to lay off hundreds of North Jersey-based employees

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

11 月前 · Reuters

Novartis to acquire Tourmaline Bio for $1.4 billion

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmali...

EMS-CHEMIE HOLDING AG (EMSN.SW)

關於 EMSN.SW

財務表現

分析師預測